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Novel Locally Active Estrogens 
Accelerate Cutaneous Wound 
Healing-Part 2
Mario Brufani1, Nicoletta Rizzi5, Clara Meda5, Luigi Filocamo  1, Francesca Ceccacci  4, 
Virginia D’Aiuto2,3, Gabriele Bartoli2,3, Angela La Bella2,3, Luisa M. Migneco2,3, Rinaldo Marini 
Bettolo2,3, Francesca Leonelli4, Paolo Ciana5 & Adriana Maggi5
Estrogen deprivation is associated with delayed healing, while estrogen replacement therapy (ERT) 
accelerates acute wound healing and protects against development of chronic wounds. However, 
current estrogenic molecules have undesired systemic effects, thus the aim of our studies is to generate 
new molecules for topic administration that are devoid of systemic effects. Following a preliminary 
study, the new 17β-estradiol derivatives 1 were synthesized. The estrogenic activity of these novel 
compounds was evaluated in vitro using the cell line ERE-Luc B17 stably transfected with an ERE-Luc 
reporter. Among the 17β-estradiol derivatives synthesized, compounds 1e and 1f showed the highest 
transactivation potency and were therefore selected for the study of their systemic estrogenic activity. 
The study of these compounds in the ERE-Luc mouse model demonstrated that both compounds lack 
systemic effects when administered in the wound area. Furthermore, wound-healing experiments 
showed that 1e displays a significant regenerative and anti-inflammatory activity. It is therefore 
confirmed that this class of compounds are suitable for topical administration and have a clear 
beneficial effect on wound healing.
Large experimental evidence demonstrated that the sex steroid estrogen protects against developing a chronic 
wound1, delays delayed healing, particularly in the elderly2, and estrogen replacement accelerates healing in aged 
humans and hormone-deprived animal models3, 4. Several studies addressed the mechanisms underlying such 
an effect and showed that estrogenic compounds play a prominent role in promoting the healing processes by 
modulating the inflammatory response, accelerating re-epithelialization, inducing granulation, and modifying 
proteolysis in skin cells, especially keratinocytes5, 6.
Recent studies provided new insights on the molecular mechanisms mediating the estrogen protective func-
tion. It is now known that macrophages and neutrophils express the intracellular receptors for estrogens (ERα 
and ERβ) and in these cells the 17β-estradiol-ER complex may exert anti-inflammatory activity by inhibiting 
NF-kB nuclear translocation7 and by accelerating macrophage transition from the inflammatory phase to the so 
called M2 polarization stage that is involved in tissue repair and reconstruction8.
Considering the necessity to find efficacious therapeutic means for healing of wounds, particularly in the elder 
population, estrogens should be taken in consideration, yet the serious, undesired side effects, particularly cancer 
promotion, associated with the use of these hormones prevents their therapeutic application. Therefore, to exploit 
the beneficial effects of estrogens on wound healing, while avoiding their undesired side effects, we attempted to 
obtain locally active estrogens.
Some years ago we reported the synthesis and pharmacological activity of alkyl ester 2, derivatives of 
17β-estradiol at C-179.
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In these compounds the metabolite resulting from the hydrolysis of the ester group is an alcohol that can 
quickly undergo metabolic oxidation, and therefore further loses affinity for ERs10–13. In fact, compound 2e, with 
the highest transactivation potency, showed in vivo substantially accelerated healing without systemic activity. 
Continuing these studies, we decided to generate a series of novel ester derivatives of 17β-estradiol at C-17 in 
which the metabolic hydrolysis would generate directly a carboxylic acid (Fig. 1).
We here show the studies carried out with topic application of these compounds that demonstrate their effi-
cacy in wound healing and their lack of effects at systemic level.
Results and Discussion
Synthesis of Compounds 1. The starting material for the synthesis of compounds 1 were the known 
17β-estradiol derivatives 3, whose preparation we have previously described9. The first step in the synthesis 
was conversion of 3 to the corresponding carboxylic acids 4 by means of a 2,2,6,6-tetramethylpiperidinyloxy 
(TEMPO) catalyzed oxidation, using NaClO2 as stoichiometric oxidant (Fig. 2)14.
Compounds 4 were then converted into compounds 5 by esterification with a number of alcohols in the pres-
ence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) and 4-dimethylaminopyridine 
(DMAP)15. Deprotection of the phenol function with p-toluensulphonic in a MeOH/H2O mixture gave the target 
compounds 1. Compounds 3 were eventually unprotected with p-toluensulphonic in a MeOH/H2O mixture to 
Figure 1. Chemical structures of 17β-estradiol and derivatives 1 and 2.
Figure 2. Reagents and reaction conditions. (a) NaClO, NaClO2, TEMPO, Phosphate buffer, CH3CN, 38 °C. (b) 
EDC, HCl, ROH, DMAP, rt. (c) PTSA, MeOH, H2O, rt. (d) 0.1 M KOH/EtOH.
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give 17β-estradiol derivatives 6. Finally, 1b was submitted to basic hydrolysis to give 7(H-NMR and C-NMR 
spectra of new 17β-estradiol derivatives 1, 6 and 7 are shown in Supplementary Information).
Estrogenic Activity of the New Chemical Entities (NCE). In vitro studies - cell transfection assay. The 
ability of the novel compounds to transcriptionally activate ERs was tested in ERE-Luc B17 cells, a clone of the 
breast cancer cell line MCF-7 stably transfected with a reporter constituted by the luciferase gene driven by an 
estrogen-regulated synthetic promoter previously generated and tested in our laboratories16. Several compounds 
displayed a transactivation potency (EC50) of an order of magnitude compatible for therapeutic use as most syn-
thesized compounds had an EC50 between 2.3 × 10−6 and 9.8 × 10−7 M. The highest transactivation activity was 
shown by compound 1e and 1f with an EC50 of 1.3 × 10−9 and 7.9 × 10−8 M, respectively. Compounds 1b, 6a and 
1h did not show any activity on ERs (Fig. 3).
The compounds 1e and 1f were therefore selected for a further study to evaluate their estrogenic activity in 
vivo.
In vivo imaging. To investigate the activity of 1e and 1f at systemic level, we utilized the ERE-Luc reporter 
mice. The ERE-luc is a transgenic model obtained by random integration of a luciferase reporter driven by an 
estrogen-responsive promoter. The ubiquitous, regulated expression of luciferase was obtained by flanking the 
reporter construct with insulators15. A large number of experimental evidence demonstrates that in this mouse 
luciferase activity is strictly correlated with the state of ER transcriptional activity16–18 and that the sensitivity of 
the response to estrogen is sufficient to measure by total body in vivo bioluminescence the subtle physiological 
changes in ER activity typical of the different phases of the reproductive cycle.
Here, the first study we carried out was a large-range dose-response analysis to measure whole body luciferase 
assay after subcutaneous administration of: (1) the vehicle; (2) corn oil as control; (3) the two compounds 1e and 
1f at the dosage of 20 μg/kg, 200 μg/kg, 2 mg/kg and 20 mg/kg. The mice (4 for each experimental group) were 
subjected to in vivo whole body imaging 6 h after the pharmacological treatment. This time was selected on the 
basis of previous studies showing that the peak of ER transcriptional activation generally occurs at 6–8 h after 
administration of the estrogenic compounds16, 17. The administration of 20 and 200 μg/kg of 1e and 1f did not 
induce any measurable effect at systemic level, at the higher dosages (2 and 20 mg/kg) both compound 1e and 1f 
induced the expression of the luciferase reporter around the area of subcutaneous injection and in some other 
body areas (Fig. 4).
This observation suggested that 1e and 1f up to the dose of 200 μg/kg acted locally by showing some activity 
at the administration site, but not a systemic level and led us to further evaluate their effects in a wound healing 
model.
Properties of 1e and 1f when administered in the area surrounding a wound. To study the estrogenic and healing 
properties of the two compounds, we generated a wound in the ERE-Luc mouse model and tested the activity of 
the two compounds administered s.c. in the area surrounding the wound as described in the methodology section.
The study was done in the following experimental groups: (1) vehicle (corn oil), (2) 1e (200 µg/kg s.c.); (3) 1f 
(200 µg/kg s.c.) and 4) 17β-estradiol (20 µg/kg s.c.) as positive control. Each group was composed of 4 ERE-Luc 
females’ mice ovariectomized 2 weeks’ prior the experiment to avoid any interference due to endogenous estro-
gens. Photon emission was measured in the living animals three times: at 0, 3 and 6 h after s.c. injection. Figure 5 
shows the images of the mice in pseudocolors as obtained by the CCD camera in panel a and the measurement of 
the amount of photon emission by whole body, thymus, hepatic area, abdomen, limbs, vagina (ventral view) and 
in wound area (dorsal view) in panel b.
Most relevant was the fact that we did not observe increased photon emission in any of the body areas taken into 
consideration at 3 or 6 h after the topic administration of 1e and 1f; in contrast, 17β-estradiol treatment induced a 
significant increase of luciferase activity in the whole body and in several of the body areas analyzed. In the wound 
area photon emission measured at 6 hours time showed a trend to increase in animals treated with both 1e and 1f 
(30% and 20% increase with respect to time 0, respectively). In this area 17β-estradiol induced a 40% increase with 
respect to vehicle-treated mice; no increase was registered in the animals treated with the vehicle.
We next examined photon emission in a series of organs excised from the mice euthanized at 6 hours after 
treatment by measuring photon emission with the CCD camera (Fig. 6a) and by the more sensitive enzymatic 
assay in tissue extracts of each organ (Fig. 6b). This latter experiment clearly demonstrated that, contrary to 
17β-estradiol, the two NCE did not induce bioluminescence in any of the organs investigated and further indi-
cated that 1e and 1f were devoid of any systemic activity.
The final study aiming at investigating the systemic effect of the NCE was done by measuring the uterus weight 
of all treated animal as the golden standard for the quantitative measure of estrogenic compounds. Figure 7 shows 
that, 6 h after treatment, with 1e and 1f the weight of the uterus was indistinguishable from controls; conversely, 
the average uterus weight of the mice treated with 17β-estradiol was 22.8 mg, i.e 35% higher than the average 
weight of controls (n = 4).
Proliferative potential and healing efficiency of 1e and 1f when administered. Wound healing is a dynamic process 
consisting of four continuous, overlapping, and precisely programmed phases: hemostasis, inflammation, pro-
liferation and tissue growth (proliferation) and remodeling (maturation). The healing effect of estrogens may be 
exerted at several levels, certainly the ability of the hormone to accelerate macrophage polarization towards the 
M2-reparative polarization stage plays a relevant role, however estrogens may also facilitate local cell proliferation 
and the formation of the granulation tissue, epithelialization, and wound contraction. We therefore planned to 
carry out experiments with the MITO-Luc19 a transgenic mouse carrying a reporter of mitosis, aimed at demon-
strating the local and systemic proliferative potential of the synthetic estrogens we generated.
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The experiments were done with the 1e compound as completely deprived of any activity on the uterus 
(Fig. 6). Ovariectomized MITO-Luc mice (n = 4 each group) were injected with vehicle (corn oil), 200 µg/kg 1e 
and 20 µg/kg 17β-estradiol subcutaneously in the area surrounding the wound. Photon emission was measured 
Figure 3. Compounds: chemical structure of tested compounds. Dose-response: ER transcriptional activity 
measured as luciferase activity in the presence of increasing concentrations of indicated compounds in the ERE-
Luc B17 cells, fold induction of luciferase activity measured at 10-5 M of indicated compound respect to vehicle. 
EC50: plotting of the transactivation data for EC50 calculation by means of sigmoidal dose-response (variable 
slope) using PRISM5 software.
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in the wound area at the following time: 0, 24, 48 and 72 hours post-treatment. Figure 8 shows that, 48 hours 
after administration of 1e and 17β-estradiol, photon emission from the wound area was significantly increased; 
the maximal activity of both treatments with 1e and 17β-estradiol was observed at h 72 (87% increase of photon 
emission from wound of animals treated with 200 µg/kg 1e and 78% increase in 20 µg/kg 17β-estradiol treated 
animals). In animals treated with the vehicle photon emission was also increased, but at much lower extent 
(+13% versus time 0), indicating that both 1e and 17β-estradiol were able to regulate the extent of proliferation 
in the area surrounding the wound (Fig. 8).
To investigate to which extent the increased proliferation observed after the pharmacological treatments was 
functional to the healing process, we measured the size of the wound (Fig. 9a). 72 hours after the treatments we 
observed a 73% wound area reduction in 1e treated animals, 60% in 17β-estradiol treated animals and 50% in 
vehicle animals. These data suggested that 1e accelerates wound healing.
To better understand whether the healing effect of 1e could be attributed to its anti-inflammatory action, 
at the end of in vivo imaging (72 hours after treatments) the tissue surrounding the wound was dissected and 
subjected immunohistochemical analysis using the pan macrophage marker Iba1. As shown in Fig. 9b, in the 
animals treated with 1e and 17β-estradiol the number of macrophages in the wound area significantly lower than 
in controls (25% and of 44% respectively). This observation confirmed that the estrogenic compounds were able 
to regulate the immune response at local level.
Next, we investigated the effects of 1e with respect to 17β-estradiol using ovx MITO-Luc mice at longer time. 
The first day of the experiment, one round full thickness wound was made on each mouse (n = 2) and then all 
mice were treated with vehicle, 200 µg/kg 1e or 20 µg/kg 17β-estradiol by subcutaneous injection around the 
round wound. The measure of photon emission from the wound area was done for several days after the wound-
ing. 3 days after treatment the bioluminescent signal is highest (Fig. 10 Panel a). The intensity of photon emission 
was significantly decreased 2 days later and kept decreasing to reach, at day 10, values very comparable to those 
measured before the wounding (time = −1 day). The histological analyses done on the explanted wound tissues 
at day 10 showed that in the animals treated with 1e there was a significantly higher granulation tissue than (his-
toscore mean = 1.5) in those injected with vehicle (histoscore mean = 0.3) (Fig. 10 panel b).
Comparative analysis of 1e and 17β-estradiol systemic proliferative activity. The study was done in the MITO-Luc 
mice. Photon emission was measured in the following body areas: head, sternum, vagina, femur and breast 
Figure 4. Effect of NCE on ER transcriptional activity in living ERE-Luc mice: dose- response. (a) Optical 
imaging of ERE-Luc mice at 0 and 6 hours after treatment with the indicated dosages of 1e compound. Photos 
portray whole body (ventral view) of a representative individual in a pseudocolor image indicating the intensity 
of photon emission from the different body areas. (b) In vivo BLI: quantification of photon emission whole 
body at 0 and 6 hours after injection of 1e at indicated dosages. (c) Optical imaging of ERE-Luc mice at 0 and 
6 hours after treatment with the indicated dosages of 1f compound. Photos portray whole body (ventral view) in 
a pseudocolor image processed to indicating the intensity of photon emission from the different body areas of a 
representative animal for each group. (d) Whole body photon emission quantification at 0 and 6 hours after 1f 
treatment at indicated doses. Bars correspond to mean +/− SEM (n = 4).
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Figure 5. Time-course analysis of ER activity in selected body areas after administration of synthetic and 
natural estrogens. (a) Optical imaging of ERE-Luc mice at 0, 3 and 6 hours after the s.c. injection of the indicated 
compounds. Photos portray whole body (ventral and dorsal view) pseudocolor images representing the amount 
of photon emission. Each individual is representative of its own group. (b) In vivo BLI: photon emission from 
selected body areas were measured. Bars represent the mean +/− SEM of photon emission measured in 4 
animals/group. *p < 0.05; **p < 0.01; ***p < 0.001 vs time 0 ANOVA followed by Bonferroni’s test for multiple 
comparisons.
Figure 6. Analysis of the systemic effect of 1e and 1f compounds to female ERE-Luc ovx mice. (a) Ex vivo BLI: 
photon emission measured in each organ as indicated. (b) Enzymatic Luciferse assay: luciferase enzymatic 
assay performed in indicated tissue. Bars represent the mean +/− SEM of photon emission measured in 4 
animals/group. **p < 0.01 vs vehicle ***p < 0.001 vs vehicle ANOVA followed by Bonferroni’s test for multiple 
comparisons.
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Figure 7. Uterus weight of ERE-Luc mice treated with synthetic and natural estrogens. Analysis of average 
weight of uterus of ERE-Luc mice after 6 hours of indicated treatment. Bars represent the mean ± SEM of uterus 
weigh measured in 4 animals/group.
Figure 8. Proliferation analysis. (a) In vivo wound healing bioluminescence imaging of MITO-Luc after 
indicated treatments. Photos portray whole body (dorsal view) at 0, 24, 48, 72 hours after treatments, in a 
pseudocolor image processed to indicate the intensity of photon emission in wound areas. (b) In vivo BLI: 
quantification of photon emission in the wound area at the indicated time point. Each bar represents the mean 
ratio versus time = 0 h +/− SEM of photon emission measured in 4 animals/group. *p < 0.001 vs time 0, 
ANOVA followed by Bonferroni’s test for multiple comparisons.
www.nature.com/scientificreports/
8Scientific RepoRts | 7: 2510  | DOI:10.1038/s41598-017-02820-y
(ventral view, as indicated in Fig. 11a) at 0, 24, 48 and 72 hours after the local, s. c., injection of vehicle, 200 µg/kg 
1e and 20 µg/kg 17β-estradiol (n = 4). No increase of bioluminescence was measured in 1e treated animals respect 
to vehicle at any time point (Fig. 11b).
This was not the case with the animals treated with 17β-estradiol where 48 hours after the local s.c. injec-
tion of 17β-estradiol we observed that the bioluminescent signal showed a trend to increase, likely due to the 
uterotrophic effect of the hormone. This observation further underlines the lack of systemic effects of the 1e 
compound.
Conclusions
In the present study we have prepared a family of compounds active through the ER characterized by a structure 
that should ensure their rapid metabolism and limited systemic action when administered in vivo. Most of com-
pounds tested, and in particular 1e and 1f, showed a significant affinity for ERs and were able to efficiently induce 
ER transcriptional activity.
The biological activity of 1e tested in a well-characterized wound healing murine model8 showed a signifi-
cant effect on wound healing and inflammatory processes. 1e proved to be very effective in accelerating healing. 
Several studies suggest that the beneficial effects of estrogens on the healing process is in the dampening of the 
inflammatory response, in particular it was reported that accelerated healing was correlated with a reduction 
in infiltrating macrophages numbers1, 3, 4. The current study supports this view by showing a decreased num-
ber of Iba1 positive macrophages in the granulation tissue (Fig. 9b); the increase of proliferation in the 1e and 
17β-estradiol treated animals may be in line with the view of an accelerated transition from inflammatory phase 
to proliferative phase. In this regard, 1e showed an activity comparable to that one of the natural estrogen. Most 
importantly, 1e administered s.c. at the dose of 200 μg/kg in the wound area proved to be devoid of systemic 
effects as indicated by the lack of ER transcriptional activity in the ERE-Luc model, of bioluminescence signaling 
Figure 9. Reduction of the wound areas after treatment with 1e and 17β-estradiol. (a) Wound area 
measurement: each bar represents the mean ratio versus time = 0 h +/− SEM expressed as percentage of wound 
area measured in 4 animals/group. (b) Representative staining of wound explants at 72 hours after treatments. 
Staining was done with Iba1 antibody. Pictures were taken at 25x and 400x. Bar = 2 mm. The number of 
macrophages cells around wound site: each bar represents the mean +/−SEM, macrophages (Iba1 positive 
cells) were counted by analyzing n = 6 fields (vehicle), n = 11 fields (1e) and n = 10 fields (17β-estradiol) at 400x 
enlargement. (*p < 0.1 vs vehicle, ANOVA followed by Bonferroni’s test for multiple comparisons).
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in the MITO-Luc mouse and the lack of uterotrophic effect. All parameters were clearly affected by 17β-estradiol 
(Figs 5, 6 and 11).
Our study, by identifying a new class of molecules locally active through the ERs in the wound healing pro-
cess confirms the results of our previous work and add new avenues in the search of novel drugs for a still unmet 
medical need.
Methods
Materials and Methods. All solvents were analytical grade. TLC: Merck silica gel 60 F254. CC: silica gel 60, 
70–230 mesh ASTM. IR spectra: Shimadzu-FTIR 8400S infrared spectrophotometer, in cm-1. 1H and 13C NMR: 
Bruker AC 300P operating at 300.13 and 75 MHz respectively; compound purity was evaluated by HPLC analysis: 
Shimadzu LC-10AD; RID detector; column, Macherey-Nagel 250/4 Nucleosil 100-5; flow, 0.8 mL/min; T, 35 °C; 
all solvents were HPLC grade; tR in min. Mp: Mettler-FP-61 apparatus (uncorrected). HR mass spectra were 
recorded with a Micromass Q-TOF micro mass spectrometer (Waters). FIA-MS experiments were performed 
on a linear ion trap mass spectrometer (LXQ Thermo Finningan) equipped with a heated electrospray ionization 
(HESI) source. Operating conditions of the HESI were as follows: source temperature: 50 °C; ion spray volt-
age = +4.0 kV; sheath gas = 5 (arbitrary scale); capillary temperature = 275 °C. Methanolic solutions of samples 
(1 × 10−5 M) were infused via a syringe pump at a flow rate of 3–5 μL/min. Unless otherwise specified, all organic 
solutions were dried over anhydrous Na2SO4 and evaporated to dryness under reduced pressure.
General procedure of the preparation of compounds 1. A mixture of 38 (1.0 mmol) in CH3CN 
(40 mL), TEMPO (30 mg, 0.19 mmol) and sodium phosphate buffer (0.67 M, 6 mL, pH 6.7) was stirred at 40 °C. 
To this mixture, NaClO (5.25%, 0.24 mL, 0.20 mmol) and NaClO2 (80%, 0.34 g, 3.0 mmol) were added portion-
wise simultaneously.
The solution became slowly brownish and was left under stirring at 40 °C till disappearance of the starting 
material (generally 2–4 hours, TLC: EtOAc). To the reaction mixture H2O (40 mL) was added and pH adjusted to 
8 with 4N NaOH. The reaction flask was then cooled to 0 °C and quenched with a Na2SO3 aqueous solution (2 g in 
30 mL). The whole was then extracted with methyl-t-butylether and the organic phase discarded. After adjusting 
Figure 10. 1e compound and 17β- estradiol accelerate wound healing. (a) In vivo BLI: round wound area 
photon emission quantification at indicated time point in MITO-Luc mice. Each bar represents the mean ratio 
versus time = 0 h +/− SEM of photon emission measured in 2 animals/group. (**p < 0.01 vs 0 h, ANOVA 
followed by Bonferroni’s test for multiple comparisons). (b) Hematoxylin-eosin representative staining of 
wound section at 10 days after the indicated treatments. The histoscore value for granulation tissue (fibrosis) is 
shown as mean, each histoscore consists of 4 random fields/groups, the criteria for the assignation of histoscore 
value are: 1 = wound bed partially covered with granulation tissue; 2 = thin granulation over the whole wound 
bed; 3 = thick granulation over the whole wound bed. Bar = 2 mm.
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the pH to 4 the aqueous phase was thoroughly extracted with EtOAc. Combined organic phases were washed 
with water, brine, dried over anhydrous Na2SO4 and evaporated to dryness to give carboxylic acids 4. The latter 
was used as crude in the next reaction. Thus to an ice-bath cooled solution of 4 and DMAP (30 mg, 0.25 mmol) 
in the proper alcohol (20 mL), EDC (0.23 g, 1.2 mmol) was slowly added in 40 minutes. The ice bath was removed 
and the whole allowed to stir at rt till disappearance of the starting material (generally 20 hours, TLC: EtOAc/hex-
ane = 6/4). The mixture was then concentrated under reduced pressure, H2O was added and the whole extracted 
with EtOAc. The combined organic phases were washed with NaHCO3 s.s., brine, dried over anhydrous Na2SO4 
and evaporated to dryness to give crude 5.
The crude product of the previous reaction was dissolved in MeOH (20 mL) and a 0.1 M p-toluensulphonic 
acid solution was added to adjust the pH to 2. The resulting solution was left under stirring at rt until TLC 
showed the complete disappearance of the starting material (generally 1 h). The solution was then diluted with 
EtOAc (80 mL) and washed to neutrality with a saturated NaHCO3 aqueous solution, and the aqueous phase was 
extracted with EtOAc. The combined organic phases were collected, washed with brine and dried. After filtration, 
evaporation of the solvent and purification of the crude product, gave 1 as a pale yellow viscous oil.
3,17β-Hydroxy-17α-(4′carbomethoxy-1′-butyn-1′-yl)estra-1,3,5-(10)-triene (1a). Yield: 70%
CC: EtOAc/n-hexane, from 2/8 to 3/7
1H NMR(CDCl3): 7.15 (d, J = 8.4 Hz, 1 H), 6.63 (dd, J1 = 2.7, J2 = 8.4 Hz, 1 H), 6.57 (d, J = 2.7 Hz, 1H), 3.69 (s, 
1H), 2.84–2.76 (m, 2H), 2.57 (s, 3H), 2.38–2.12 (m, 4H), 2.03–1.22 (m, 12H), 0.86 (s, 3H).
13C NMR(CDCl3): 172.6, 153.5, 138.4, 132.7, 126.7, 115.4, 112.8, 84.7, 84.4, 80.0, 52.0, 49.6, 47.0, 43.7, 39.6, 
39.1, 33.8, 33.0, 29.8, 27.3, 26.6, 22.9, 15.0, 12.9.
IR (CHCl3): 3599, 2933, 1734.
HPLC: EtOAc/n-hexane = 27/73; tR = 19.2 min, purity = 97.8%.
HRMS(ESI): Calc for C24H30O4 405.2042 (M + Na)+; found 405.2053.
3,17β-Hydroxy-17α-(4′carbethoxy-1′-butyn-1′-yl)estra-1,3,5-(10)-triene (1b). Yield: 65%
CC: EtOAc/n-hexane = 2/8
1H NMR(CDCl3): 7.13 (d, J = 8.4 Hz, 1 H), 6.65 (dd, J1 = 2.5 Hz, J2 = 8.3 Hz, 1H), 6.58 (d, J = 2.3 Hz, 1H), 4.16 
(q, J = 7.1, 2H), 2.88–2–73 (m, 2H), 2.62–2.51 (m, 4H), 2.40–2.10 (m, 3H), 2.09–1.91 (m, 2H), 1.90–1.55 (m, 5H), 
1.53–1.22 (m, 7H), 0.84 (s, 3H).
13C NMR(CDCl3): 172.5, 153.7, 138.2, 132.3, 126.5, 115.4, 112.9, 84.6, 84.3, 80.1, 61.0, 49.5, 47.3, 43.7, 39.6, 
39.0, 34.0, 32.9, 29.7, 27.3, 26.5, 22.9, 14.9, 14.3, 12.9.
IR(CHCl3): 3595, 2360, 2343, 1732.
HPLC: EtOAc/n-hexane = 30/70; tR = 8.8 min, purity = 94.8%.
HRMS(ESI): Calc for C25H32O4 419.2198 (M + Na)+; found 419.2219.
Figure 11. 1e compound does not induce proliferation at systemic level in the MITO-Luc mouse. (a) In vivo 
whole body bioluminescence imaging of MITO-Luc after indicated treatments. Photos portray whole body 
(ventral view) at 0, 24, 48, 72 hours after treatments in a pseudocolor image processed to indicating the intensity 
of photon emission in whole body. (b) In vivo BLI: photon emission from selected body areas were measured. 
Bars represent the mean ratio versus t = 0 h and vs vehicle ± SEM of photon emission measured in 4 animals/
group.
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3,17β-Hydroxy-17α-(4′carbopropoxy-1′-butyn-1′-yl)estra-1,3,5-(10)-triene (1c). Yield: 61%
CC: EtOAc/n-hexane = 2/8
1H NMR (CDCl3): 7.15 (d, J = 8.3 Hz, 1H), 6.64 (dd, J 1 = 2.7 Hz, J 2 = 8.4 Hz, 1H), 6.57 (d, J = 2.6 Hz, 1H), 4.05 
(t, J = 6.7 Hz, 2H), 2.87–2.76 (m, 2H), 2.62–2.52 (m, 4H), 2.37–2.11 (m, 3H), 2.07–1.92 (m, 2H), 1.90–1.56 (m, 
7H), 1.53–1.21 (m, 4 H), 0.93 (t, J = 7.4 Hz, 3H), 0.85 (s, 3H).
13C NMR (CDCl3): 172.4, 153.5, 138.4, 132.7, 126.7, 115.4, 112.8, 84.6, 84.5, 80.1, 66.5, 49.5, 47.3, 43.7, 39.5, 
39.1, 34.0, 33.0, 29.8, 27.3, 26.6, 22.9, 22.1, 15.0, 12.9, 10.5.
IR (CHCl3): 3390, 2330, 1728.
HPLC: EtOAc/n-hexane = 30/70; tR = 7.6 min, purity = 91.2%.
HRMS(ESI): Calc for C26H34O4 433.2355 (M + Na)+; found 433.2371.
3,17β-Hydroxy-17α-(4′carbo-iso-propoxy-1′-butyn-1′-yl)estra-1,3,5-(10)-triene (1d). Yield: 
45%
CC: EtOAc/n-hexane = 2/8
1H NMR (CDCl3): 7.14 (d, J = 8.4 Hz, 1H), 6.64 (dd, J 1 = 2.7 Hz, J 2 = 8.4 Hz, 1H), 6.57 (d, J = 2.6 Hz, 1H), 
5.03(spt, J = 6.2 Hz, 1H), 2.85–2.75 (m, 2H), 2.63–2.44 (m, 4H), 2.36–1.10 (m, 20H), 0.86 (s, 3H).
13C NMR (CDCl3): 171.9, 153.6, 138.3, 132.6, 126.6, 115.4, 112.8, 84.6, 84.5, 80.1, 68.4, 49.5, 47.3, 43.7, 39.6, 
39.1, 35.0, 33.0, 29.8, 27.3, 26.6, 22.2, 21.9, 15.0, 12.9.
IR (CHCl3): 3414, 1724.
HPLC: EtOAc/n-hexane = 27/73; tR = 8.9 min, purity = 99.7%
HRMS(ESI): Calc for C26H34O4 433.2355 (M + Na)+; found 433.2364.
3,17β-Hydroxy-17α-(4′carbobutoxy-1′-butyn-1′-yl)estra-1,3,5-(10)-triene (1e). Yield: 65%
CC: EtOAc/n-hexane = 2/8
1H NMR (CDCl3): 7.13 (d, J = 8.4 Hz, 1H), 6.65 (dd, J1 = 2.5 Hz, J 2 = 8.4 Hz, 1H), 6.58 (d, J = 2.4 Hz, 1H), 4.10 
(t, J = 6.6 Hz, 2H), 2.88–2.73 (m, 2H), 2.65–2.49 (m, 4H), 2.37–2.10 (m, 3H), 2.09–1.92 (m, 2H), 1.90–1.54 (m, 
7H), 1.53–1.22 (m, 6H), 0.92 (t, J = 7.3 Hz, 3H), 0.86 (s, 3H).
13C NMR (CDCl3): 172.5, 153.7, 138.3, 132.4, 126.6, 115.4, 112.8, 84.6, 84.4, 80.1, 64.9, 49.5, 47.3, 43.7, 39.5, 
39.0, 34.0, 33.0, 30.7, 29.8, 27.3, 26.6, 22.9, 19.2, 15.0, 13.8, 12.9.
IR (CHCl3): 3597, 1732.
HPLC: EtOAc/n-hexane = 30/70; tR = 6.9 min, purity = 94.4%.
HRMS(ESI): Calc for C27H36O4 447.2511 (M + Na)+; found 447.2520.
3,17β-Hydroxy-17α-(4′carbamyloxy-1′-butyn-1′-yl)estra-1,3,5-(10)-triene (1f). Yield: 50%
CC: EtOAc/n-hexane = 2/8
1H NMR (CDCl3): 7.12 (d, J = 8.4 Hz, 1H), 6.67 (dd, J 1 = 1.9 Hz, J 2 = 8.4 Hz, 1H), 6.60 (d, J = 1.9 Hz, 1H), 4.10 
(t, J = 6.8 Hz, 2H), 2.87–2.68 (m, 2H), 2.57 (s, 4H), 2.37–1.24 (m, 19H), 0.92–0.87 (m, 6H).
13C NMR (CDCl3): 172.7, 153.8, 138.0, 132.1, 126.4, 115.4, 112.8, 84.6, 84.2, 80.0, 65.2, 49.4, 47.2, 43.6, 39.5, 
38.9, 33.9, 32.9, 29.7, 28.3, 28.0, 27.3, 26.5, 22.8, 22.3, 14.9, 14.0, 12.9.
IR (CHCl3): 3597, 2933, 1732.
HPLC: EtOAc/n-hexane = 30/70; tR = 6.6 min, purity = 94%.
HRMS(ESI): Calc for C28H38O4 461.2668 (M + Na)+; found 461.2655.
3,17β-Hydroxy-17α-(5′carbomethoxy-1′-butyn-1′-yl)estra-1,3,5-(10)-triene (1g). Yield: 51%
CC: EtOAc/n-hexane from 2/8 to 4/6
1H NMR (CDCl3): 7.16 (d, J = 8.5 Hz, 1H), 6.63 (dd, J 1 = 8.4 Hz, J 2 = 2.7 Hz, 1H), 6.56 (d, J = 2.7, 1H), 3.67 (s, 
3H), 2.90–2.70 (s, 2H), 2.51–1.30 (m, 19H), 0.86 (s, 3H).
13C NMR (75.47 MHz, CDCl3): δ = 173.9, 153.5, 138.4, 132.8, 126.7, 115.4, 112.8, 85.171, 84.8, 80.2, 51.8, 49.7, 
47.3, 43.8, 39.6, 39.3, 33.1, 29.8, 23.8, 26.6, 24.1, 22.9, 18.5, 13.0.
IR (CHCl3): 3599, 2933, 1734.
HPLC: EtOAc/n-hexane = 27/73; tR = 17.3 min, purity = 94.2%.
HRMS(ESI): Calc for C25H32O4 419.2198 (M + Na)+; found 419.2180.
3,17β-Hydroxy-17α-(5′carbethoxy-1′-butyn-1′-yl)estra-1,3,5-(10)-triene (1h). Yield: 51%
CC: EtOAc/n-hexane = 2/8
1H NMR (CDCl3): 7.17 (d, J = 8.4 Hz, 1H), 6.63 (dd, J 1 = 2.1 Hz, J 2 = 8.4 Hz, 1H), 6.56 (s,1H), 4.13 (q, 
J = 7.2 Hz, 2H), 2.89–2.68 (m, 2H), 2.47–1.15 (m, 22H), 0.87 (s, 3H).
13C NMR (CDCl3): 173.5, 153.6, 138.4, 132.7, 126.7, 115.4, 112.8, 85.3, 84.8, 80.2, 60.6, 49.6, 47.3, 43.8, 39.6, 
39.2, 33.4, 33.1, 29.8, 27.4, 26.6, 24.1, 22.9, 18.4, 14.3, 13.0.
IR (CHCl3): 3597, 3391, 2937, 1728.
HPLC: EtOAc/n-hexane = 27/73; tR = 13.8 min, purity = 99.9%.
HRMS(ESI): Calc for C26H34O4 433.2355 (M + Na)+; found 433.2340.
3,17β-Hydroxy-17α-(4′carboxy-1′-butyn-1′-yl)estra-1,3,5-(10)-triene (7). To a rt stirred solution 
of 1b (0.10 mmol) in EtOH (12 mL) a 0.1 M KOH solution (10 mL) was added. The whole was allowed to stir for 
2 h when TLC monitoring (EtOAc/hexane = 6/4) showed the reaction completion. The reaction mixture was then 
acidified with 0.1 M HCl and thoroughly extracted with EtOAc. Combined organic extracts were washed with 
brine, dried and evaporated to dryness to give crude 7 which was purified by CC (EtOAc, 90% yield).
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1H NMR (CD3COCD3): 7.09 (d, J = 8.4 Hz, 1H), 6.60 (dd, J 1 = 2.4 Hz, J 2 = 8.4 Hz, 1H), 6.52 (d, J 
1 = 2.4 Hz,1H), 2.85–2.66 (m, 2H), 2.55–2.44 (m, 4H), 2.37–2.26 (m, 1H), 2.22–2.08 (m, 2H), 2.03–1.60 (m, 6H), 
1.47–1.22 (m, 4H), 0.86 (s, 3H).
13C NMR (CD3COCD3): 173.3, 155.8, 138.4, 132.1, 127.1, 115.9, 113.6, 86.0, 84.1, 79.7, 50.1, 48.0, 44.5, 40.6, 
40.0, 34.1, 33.7, 30.3, 28.1, 27.4, 23.5, 15.3, 13.3.
IR(ATR): 3234, 1701.
HPLC: Chiralcel OB; i-PrOH/n-hexane = 15/85 + 0.1% TFA; tR = 8.1 min, purity = 98%, flow; 1 mL/min.
HRMS(ESI): Calc for C23H28O4 391.1880 (M + Na)+; found 391.1874.
General preparation of compounds 6. To a stirred solution of 3 (1.0 mmol) in 12 mL of MeOH a 0.1 M 
p-toluensulphonic acid solution was added to adjust the pH to 2. The resulting solution was left under stirring 
at rt. After complete disappearance of the starting material (generally 1 h) the solution was diluted with EtOAc 
(20 mL), washed to neutrality with a saturated NaHCO3 aqueous solution, and the aqueous phase extracted with 
EtOAc. The combined organic phases were collected, washed with brine and dried. After filtration, evaporation of 
the solvent gave crude 6, which were purified by CC.
3,17β-Hydroxy-17α-(4′hydroxy-1′-butyn-1′-yl)estra-1,3,5-(10)-triene (6a). Yield: 93%
CC: EtOAc/n-hexane 5/5
White powder
1H NMR (CD3OD): 7.10 (d, J = 8.5 Hz, 1H), 6.56 (dd, J 1 = 8.4 Hz, J 2 = 2.7 Hz, 1H), 6.49 (d, J = 2.6 Hz, 1H), 
3.69 (t, J = 6.4 Hz, 2H), 2.87–2.72 (m, 2H), 2.36 (t, J = 7.0 Hz, 3H), 2.26–2.10 (m, 2H), 2.02–2.85 (m, 3H), 1.80–
1.69 (m, 5H), 1.50–1.28 (m, 4H), 0.87 (s, 3H).
13C NMR (CD3OD): 155.9, 138.8, 132.6, 127.2, 116.0, 113.7, 85.8, 85.4, 80.6, 61.7, 50.8, 48.4, 45.2, 41.2, 40.0, 
34.2, 32.9, 30.8, 28.7, 27.8, 23.7, 16.0, 13.5.
IR(ATR): 3404, 3182.
HPLC: EtOAc/n-hexane = 50/50; tR = 15.3 min, purity = 99.9%.
HRMS(ESI): Calc for C23H30O3 377.2087 (M + Na)+; found 377.2078
Mp (EtOAc/n-hexane) = 151.6–153.3 °C.
3,17β-Hydroxy-17α-(5′hydroxy-1′-butyn-1′-yl)estra-1,3,5-(10)-triene (6b). Yield: 95%
CC: EtOAc/n-hexane from 5/5 to 6/4
White powder
1H NMR (CD3OD): 7.07 (d, J = 8.5 Hz, 1H), 6.53 (dd, J = 8.4, 2.5 Hz, 1H), 6.47 (d, J = 2.4 Hz, 1H), 3.57 (t, 
J = 6.1 MHz, 2H), 2.80–2.69 (m, 2H), 2.32–1.21 (m, 19H), 0.84 (s, 3H).
13C NMR (CD3OD): 155.8, 138.8, 132.6, 127.2, 116.0, 113.7, 86.3, 85.4, 80.5, 62.4, 50.8, 48.4, 45.2, 41.1, 40.0, 
34.2, 32.8, 30.7, 28.6, 27.7, 26.4, 23.7, 19.3, 13.5.
IR(ATR): 3373, 3227.
HPLC: EtOAc/n-hexane = 50/50; tR = 14.3 min, purity = 97.6%
HRMS(ESI): Calc for C24H32O3 391.2244 (M + Na)+; found 391.2241.
Mp (EtOAc/n-hexane) = 141.4–142.1 °C.
Cell Culture. The study was carried out using B17 clone of MCF-7 cells previously generated in our laboratory 
by stable transfection of a plasmid containing the luciferase gene under the control of an estrogen responsive pro-
moter 10. Cells were grown in RPMI 1640 supplemented with 10% FBS (Euroclone, U.K.), 50 U/mL penicillin G, 
50 µg/mL streptomicyn sulphate, 1 mM sodium pyruvate, at 37 °C at 99% humidity and 5% CO2. Cells were split 
twice a week by seeding 2 × 106 cells in 100 mm diameter Petri (Corning) dishes.
In vitro study of agonistic activity. For the in vitro measurement of activity of the new chemical entities, 
1 × 105 cells were seeded in twenty-four well plate in phenol red-free RPMI 1640 medium (Invitrogen) supple-
mented with 10% dextran-coated charcoal stripped-FBS, 1% of non-essential amino acid, 50 U/mL penicillin G, 
50 µg/mL streptomicyn sulphate, 1 mM sodium pyruvate, 2 mM L-Glutamine and kept at 37 °C in a humidified 
incubator for 24 h. Next, culture medium was replacing with phenol red-free RPMI 1640 supplemented with 1% 
stripped-FBS for a minimum of 2 h before adding 17β-estradiol or new compounds at doses indicated in a Fig. 3. 
After 24 h cells were rinsed once with PBS before preparing the protein extract for the determination of luciferase 
content. Each experiment was carried out in duplicate.
Experimental animals. ERE-Luc and MITO-Luc mice were ovariectomized at two months of age; the 
experiment was done 2 weeks after surgery to allow the animals to recover and to decrease the levels of circulating 
estrogens. The animals were fed ad libitum with a special estrogen free diet (AIN 93 M, Mucedola) (Ciana et al. 
Endocrinology 2005) and housed in individually ventilated plastic cages within a temperature range of 22–25 °C, 
relative humidity of 50% ± 10% and under an automatic cycle of 12 h light/dark (lights on at 07:00 am). All animal 
experimentation was carried out in accordance with the ARRIVE and European Guidelines for Animal Care. 
All animal experiments were approved by the Italian Ministry of Research and University and controlled by a 
Departmental panel of experts. For the correct dosage of the compounds, the body weight of the animals (on 
empty stomach, fasted for at least 12–14 hours) was determined immediately before the treatment.
Animals treatments. Ovariectomy was carried out as previously described12. Wound healing was done 
after shaving by VEET depilatory cream a day before the treatment. The 1 cm full-thickness incisional wound 
was made through the skin and panniculus carnosus muscle of ovariectomized MITO-luc using a surgical scalpel 
(blade n°10, carbon steel, Swann-Morton Ltd). Round full-thickness wounds were done by cutting out a section of 
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full-thickness skin (around 9 mm in diameter) using fine scissors on the dorsal skin of the isoflurane-anesthetized 
animal. For in vivo treatment the compounds were administered onto the subcutaneous area surrounding the 
wound by multiple subcutaneous injection, immediately after the generation of the wound.
In vivo imaging. For the semi-quantitative analysis of in vivo photon emission, animals were injected i.p. 
with 80 mg/kg of luciferin (Beetle Luciferin Potassium Salt; Promega, Madison, WI, USA) 15 min prior the imag-
ing session. For the imaging, mice were anaesthetized using isofluorane (Isofluorane-Vet; Merial, Lyon, France) 
and kept under anesthesia during the 5 minutes of the session carried out with a CCD camera: both ventral and 
dorsal acquisition (Xenogen IVIS Lumina System; Caliper, PerkinElmer company). Photon emission in selected 
body areas was measured using the Living Image Software (Caliper, PerkinElmer company). The analysis was 
done in ventral view: whole body, thymus, hepatic area, abdomen, limbs, vagina and in dorsal view in wound area 
and expressed as photon/second/cm2/steradiant (p/s/cm2/sr).
Ex vivo imaging. The selected organs were dissected from the animals who had received luciferine 20 min 
before euthanasia. The tissues were immediately subjected to ex vivo imaging session of 5 minutes. Photon emis-
sion was quantified with the Living Image Software (Caliper, PerkinElmer company) for each tissue and expressed 
as p/s/cm2/sr.
Luciferase enzymatic assay. Luciferase enzymatic activity was measured in cells or selected tissue 
homogenates by a luminometer (Glomax™96 microplate luminometer; Promega) using Promega standard lucif-
erin (Beetle Luciferin Potassium Salt) and expressed as Relative Light Units over 10 sec/μg protein (RLU/μg pro-
tein). Proteins concentrations were measured by Bradford.
Histology, immunohistochemistry and image analysis. At the time of euthanasia, the wounds with 
surrounding healthy tissue were excised, distended on a strip of hard paper and fixed in 10% buffered forma-
lin (pH = 6). Fixed samples were cut through the center of the wound and each half was embedded in paraffin 
“sideways on”. All fixed samples underwent routine processing in an automatic tissue processor and then paraffin 
embedding was carried out according to standard procedures. For histopathological examination 4 µm sections 
were routinely stained with Hematoxylin-Eosin (HE) and evaluated under a light microscope. The degree of 
re-epithelialization, the type and amount of granulation tissue and inflammation, which are the main features 
of wound healing, were scored separately. The scoring system is slightly modified compared to that applied by 
Tkalcević20.
In particular, the criteria for the assignation of granulations value are: 1 = wound bed partially covered with 
granulation tissue; 2 = thin granulation over the whole wound bed; 3 = thick granulation over the whole wound 
bed. Evaluation of macrophages was done through a specific antibody and digital image analysis: 4 µm sections 
from each wound healing sample were immunostained with primary rabbit monoclonal antibody against Iba1 
antigen (Wako; #019-19741) to assess the number of macrophages.
The number of positive cells were counted using the ImageJ analysis program (http://rsb.info.nih.gov/ij/) in 
400x microscopic fields selected at the periphery of the wound area.
Statistical analysis. Analysis of transactivation data and calculation of EC50 values were performed by 
means of sigmoidal dose-response (variable slope) using PRISM5 software (GraphPad Software Inc.).
Analysis of statistical significance was done by ANOVA followed by Bonferroni’s test for multiple comparisons.
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